Biostem Technologies (BSEM) Aktie Kurs
Biostem Technologies Kurs
De seneste 25 år voksede Biostem Technologiess omsætning med 24,3 % årligt og nåede 301,83 Mio. USD. For Biostem Technologies er nettoavance på 10,6 % op i forhold til -94,7 % for et par år siden.
Biostem Technologies aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Biostem Technologies aktie og aktieanalyse
Hyppigt stillede spørgsmål om Biostem Technologies-aktien
The business model of Biostem Technologies Inc. revolves around the development and commercialization of innovative regenerative medicine products. The company focuses on utilizing stem cells and other advanced technologies to create transformative therapies for various medical conditions. By harnessing the potential of regenerative medicine, Biostem aims to improve patients' quality of life and offer more effective treatment options. With its commitment to research and development, Biostem Technologies Inc. strives to become a leader in the regenerative medicine industry, providing hope and relief to patients worldwide.
Biostem Technologies Inc is primarily active in the biotechnology and regenerative medicine industries.
Biostem Technologies Inc faces competition in the market from various companies. Some of the main competitors of Biostem Technologies Inc include Regenexx, RepliCel Life Sciences, Cytori Therapeutics, and Histogen. These companies, like Biostem Technologies Inc, are involved in the field of regenerative medicine and offer innovative solutions for various medical conditions. However, Biostem Technologies Inc differentiates itself through its unique proprietary technologies and expertise in stem cell research. It strives to stay ahead in the market by delivering cutting-edge solutions and maintaining a strong presence in the regenerative medicine industry.
Biostem Technologies Inc is a company with a rich history and background. It was founded in [year] and has since established itself as a leading player in the [industry] sector. The company focuses on [specific focus area], offering innovative solutions and services to its clients. Biostem Technologies Inc has experienced steady growth over the years, expanding its product portfolio and geographical presence. With its strong commitment to research and development, the company has continuously introduced cutting-edge technologies that have revolutionized the [industry] industry. Today, Biostem Technologies Inc remains a trusted name in the market, backed by a talented team and a solid track record of success.
Biostem Technologies Inc has achieved several significant milestones. One notable achievement is the development of innovative stem cell therapies for various medical conditions. The company has also successfully conducted clinical trials and obtained regulatory approvals for their products. In addition, Biostem Technologies Inc has established strategic partnerships with leading medical institutions and industry experts, further strengthening its position in the field. These accomplishments demonstrate the company's commitment to revolutionizing healthcare through advanced stem cell research and its dedication to improving patients' quality of life.
Biostem Technologies Inc is primarily present in the United States.
Biostem Technologies Inc represents innovative solutions in the field of regenerative medicine. With a strong focus on research and development, the company is dedicated to harnessing the power of stem cells and other advanced technologies to provide cutting-edge medical treatments. Biostem Technologies Inc places great emphasis on scientific excellence and strives to improve patients' quality of life by offering therapies that address various medical conditions. By upholding high standards of ethics and commitment to patient care, Biostem Technologies Inc positions itself as a trusted leader in the regenerative medicine industry.
7 analytikere vurderer i øjeblikket Biostem Technologies-aktien: 6 anbefaler køb, 1 hold og 0 salg. For 2026 forventer analytikere, at Biostem Technologies genererer omsætning på 28,74 Mio. USD og indtjening pr. aktie på -4,46 USD.
Omregnet til den aktuelle valutakurs handles Biostem Technologies-aktien til 0,58 EUR (0,64 USD).
Biostem Technologies Inc is a company that specializes in the development and distribution of medical devices and therapies. The company operates in three main areas: biomedical research, stem cell therapy, and regenerative medicine. In the field of biomedical research, Biostem Technologies Inc utilizes state-of-the-art technologies to gain fundamental scientific knowledge. The company aims to conduct groundbreaking research to develop new diagnostic procedures, drugs, and therapies that improve patients' quality of life. Another area in which Biostem Technologies Inc operates is stem cell therapy. The company focuses on optimizing the body's regenerative capacity and accelerating the healing of damaged organs and tissues. The company has developed a wide range of stem cell therapies that are intended to promote rapid restoration of human health. In regenerative medicine, Biostem Technologies Inc is involved in the development of advanced and innovative technologies to accelerate the healing process and promote the regeneration of organs and tissues. The goal is to help patients restore their health naturally, without relying on invasive procedures. The company offers a wide range of products and services tailored to the needs of various customers. These include biomedical devices, blood transfusion devices, and stem cell therapies. Biostem Technologies Inc also has its own website that serves as an online store where customers can conveniently order and purchase products from the comfort of their homes. In addition to the aforementioned business areas, Biostem Technologies Inc is also active in the research and development of products for the beauty industry. The company offers a wide range of products tailored to the needs of beauty enthusiasts and customers looking to improve their skincare. The range includes anti-aging creams, shampoos and conditioners for healthy hair, as well as nail care products. Overall, Biostem Technologies Inc is a leader in biomedical research, stem cell therapy, and regenerative medicine. The company is continuously striving to further develop its products and services to meet the needs of customers and improve patients' quality of life. With its innovative capabilities and customer-oriented strategies, the company continues to thrive in the medical and beauty industry.
forventet-omsætningen for Biostem Technologies er 28,74 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Biostem Technologies er -41,23 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Biostem Technologies er i øjeblikket -0,14. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Biostem Technologies-aktien.
Pris-til-salgs-forholdet (P/S) for Biostem Technologies er i øjeblikket 0,20. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Biostem Technologies-aktien.
AlleAktien-kvalitetsscore for Biostem Technologies er 6/10.
ISIN for Biostem Technologies er US0906842002. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Biostem Technologies er A14M3B. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Biostem Technologies er BSEM. Tickersymbolet bruges til at handle Biostem Technologies-aktier på børsen.
Biostem Technologies aktie
Biostem Technologies Peer Group
Biostem Technologies Ticker
Biostem Technologies FIGI
Alle fundamentale data om Biostem Technologies i deep dive
Vores aktieanalyse af Biostem Technologies-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Biostem Technologies. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: